Inhibition of PBEF is a possible therapeutic target for pulmonary hypertension

May 22, 2012

Inhibition of pre-B Cell Colony-Enhancing Factor (PBEF) could be a potential therapeutic target for pulmonary hypertension (PH), according to a preclinical study in an animal model of PH.

"PBEF expression appears to be significantly increased in PH. Accordingly, we examined whether inhibiting PBEF could prevent and reverse PH in rats," said Roberto Machado, MD, associate professor of medicine at the University of Illinois at Chicago. "We found that PBEF not only prevented the development of PH, but was able to reverse established PH, suggesting its potential use as a therapy for PH in humans."

The results will be presented at the ATS 2012 International Conference in San Francisco.

In the study, rats were given one dose of monocrotaline to induce PH.Two sets of experiments were performed: prevention experiments,in which inhibition of PBEF was performed simultaneously with administration of monocrotaline, and reversal experiments, in which PBEF inhibition was performed two weeks after administration of monocrotaline when PH was already established in the animals.

In the prevention experiments, inhibition of PBEF prevented the development of PH and right ventricular hypertrophy. In the reversal experiments, inhibition of PBEF reversed established PH. In additional experiments in a cell culture model using human pulmonary arterial , treatment with recombinant PBEF enhanced store-operated calcium entry, which is involved in sustained pulmonary vasoconstriction and , suggesting a possible mechanism for the observed effects of PBEF inhibition in PH.

"If the prevention and reversal of PH with PPEF inhibition that we observed in our preclinical model can be replicated in humans, it might offer a new approach to the treatment of patients with PH," said Dr. Machado. "Further studies are needed to confirm and expand upon our early results."

Explore further: Trainor Lab prevents rare birth defect by inactivating p53 gene

More information: "Inhibition Of Pre-B Cell Colony-Enhancing Factor (PBEF) Prevents And Reverses Monocrotaline-Induced Pulmonary Hypertension" (Session C17, Tuesday, May 22, 2012: Room 2001-2003, Moscone Center; Abstract 29757)

Related Stories

Gene therapy may be effective in treating PAH

May 19, 2010

Gene therapy has been shown to have positive effects in rat models of pulmonary arterial hypertension (PAH), according to researchers at the University of Adelaide in Australia.

Recommended for you

New drug to fight fatal but neglected tropical disease

August 31, 2016

In a breakthrough for those infected by the parasites that cause sleeping sickness, a young Queensland researcher has identified a compound that kills the parasites in the lab without having any toxic effect on human cells.

Traces of Ebola virus linger longer than expected in semen

August 31, 2016

Initial data from a Liberian public health program show about 9 percent (38) of 429 male Ebola survivors had fragments of Ebola virus in their semen. Of those, 63 percent had semen samples that tested positive for Ebola fragments ...

Researchers discover a drug for a tropical disease

August 30, 2016

Researchers at the University of Georgia are working to find the fastest way possible to treat and cure human African trypanosomiasis, long referred to as sleeping sickness. By working to improve chemical entities already ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.